Document is current

Any future updates will be listed below

Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA adverse event reporting system

Crossref DOI link: https://doi.org/10.1186/s12885-025-13614-1

Published Online: 2025-02-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark